Enliven Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 46
- Market Cap
- $1B
- Introduction
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
- Conditions
- CML (Chronic Myelogenous Leukemia)Chronic Phase CML
- Interventions
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT06787144
- Locations
- 🇯🇵
Akita University Hospital, Akita-shi, Akita-ken, Japan
🇯🇵Aiiku Hospital, Sapporo, Hokkaido, Japan
🇯🇵Osaka University Hospital, Suita-shi, Osaka, Japan
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- Conditions
- HER2-positive Gastric CancerColorectal CancerHER2 AmplificationHER2-positive Breast CancerHER2 Positive Solid Tumors
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 275
- Registration Number
- NCT06328738
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Renato Dulbecco, Catanzaro, Italy
🇺🇸BRCR Medical Center Inc., Plantation, Florida, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
- Conditions
- HER2 Mutant Non-small Cell Lung CancerHER2-positive Metastatic Breast CancerHER2 Gene MutationHER2 Amplification
- Interventions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 198
- Registration Number
- NCT05650879
- Locations
- 🇺🇸
University of Colorado - Anschutz Medical Campus - PPDS, Aurora, Colorado, United States
🇺🇸Advent Health Orlando, Orlando, Florida, United States
🇺🇸BRCR Medical Center Inc, Plantation, Florida, United States
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- Conditions
- Chronic Myeloid LeukemiaChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveCml
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 180
- Registration Number
- NCT05304377
- Locations
- 🇮🇱
The Galilee Medical Center, Nahariya, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States